Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | SLC5A1 | P13866 | 5/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13257170 | 0.93 | KHK (0.49) | KHKLMNAKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL9892292 | 0.84 | LMNA (0.40) | KHKLMNAKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL16254892 | 0.79 | LMNA (0.68) | LMNAKDM4EL3MBTL1ALDH1A1MAPK1 | |
| SCHEMBL22060739 | 0.78 | MAPK1 (0.51) | KHKLMNAKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL22060311 | 0.78 | MAPK1 (0.51) | KHKLMNAKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL9892906 | 0.77 | LMNA (0.51) | LMNAKDM4EL3MBTL1ALDH1A1MAPK1 | |
| SCHEMBL9891530 | 0.75 | ALDH1A1 (0.52) | LMNAKDM4EL3MBTL1ALDH1A1MAPK1 | |
| SCHEMBL20458216 | 0.75 | LMNA (0.49) | LMNAKDM4EL3MBTL1ALDH1A1MAPK1 | |
| SCHEMBL9892784 | 0.75 | CNR2 (0.41) | LMNAMAPK1JAK1JAK2 | |
| SCHEMBL22060736 | 0.73 | MAPK1 (0.48) | KHKLMNAKDM4EALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443107-B1 | AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2018-08-08 | — | — | EP | disclosed |
| US-8383615-B2 | Azetidine 2-carboxamide derivatives which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-26 | — | — | US | disclosed |
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| WO-2010147791-A1 | AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142666-A1 | Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | KHK 3746/4885LMNA 4544/4885KDM4E 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.